<code id='8DE300CD93'></code><style id='8DE300CD93'></style>
    • <acronym id='8DE300CD93'></acronym>
      <center id='8DE300CD93'><center id='8DE300CD93'><tfoot id='8DE300CD93'></tfoot></center><abbr id='8DE300CD93'><dir id='8DE300CD93'><tfoot id='8DE300CD93'></tfoot><noframes id='8DE300CD93'>

    • <optgroup id='8DE300CD93'><strike id='8DE300CD93'><sup id='8DE300CD93'></sup></strike><code id='8DE300CD93'></code></optgroup>
        1. <b id='8DE300CD93'><label id='8DE300CD93'><select id='8DE300CD93'><dt id='8DE300CD93'><span id='8DE300CD93'></span></dt></select></label></b><u id='8DE300CD93'></u>
          <i id='8DE300CD93'><strike id='8DE300CD93'><tt id='8DE300CD93'><pre id='8DE300CD93'></pre></tt></strike></i>

          entertainment

          entertainment

          author:leisure time    Page View:3688
          Exterior photo of UnitedHealth Group building
          UnitedHealth Group is attempting to buy Amedisys for $3.3 billion. Courtesy UnitedHealth Group

          There’s now a two-party showdown for one of the largest home health companies in the country.

          UnitedHealth Group and its Optum division on Monday formally proposed to buy Amedisys for $100 per share, or about $3.3 billion.

          advertisement

          The offer comes a few weeks after Option Care Health proposed a $3.6 billion takeover. However, Option Care’s deal is an all-stock transaction, whereas UnitedHealth would pay all cash — a potentially more attractive offer for Amedisys shareholders who want a more immediate payout that isn’t tied to the unpredictability of another company’s stock price. Option Care’s offer is technically worth closer to $2.8 billion now, due to the drop in Option Care’s stock price since the merger was announced. Amedisys is recommending shareholders vote in favor of the deal with Option Care.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          Wikipedia

          Bright Health sells Medicare Advantage business to Molina
          Bright Health sells Medicare Advantage business to Molina

          BrightHealthisofficiallyleavingthehealthinsurancemarket.ThecompanyhasagreedtosellitsMedicareAdvantag

          read more
          Merck drug for rare lung condition set for approval in U.S.
          Merck drug for rare lung condition set for approval in U.S.

          AdobeTheFoodandDrugAdministrationisexpectedtoapproveMerck’sdrugtotreatararelungdisordercalledpulmona

          read more
          Medicare details structure of new drug price negotiation program
          Medicare details structure of new drug price negotiation program

          MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

          read more

          Syphilis numbers in the United States reach record heights

          Atissuesamplewiththepresenceofnumerous,corkscrew-shaped,darklystainedTreponemapallidumspirochetes,th